-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ZIKV-IN-1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2762166-06-1.gif)
| Category | Virus Protease |
| CAS | 2762166-06-1 |
| Description | ZIKV-IN-1 is a potent zika virus inhibitor with an EC50 of 2.8 µM and EC90 of 6.8 µM. ZIKV-IN-1 shows anti-ZIKV activity with low cytotoxicity. ZIKV-IN-1 shows a strong affinity to ZIKV RdRp domain. |
Product Information
| Synonyms | ZIKV-IN-1|HY-146957|CS-0459556 |
| Molecular Weight | 478.29 |
| Molecular Formula | C21H18BrF2N3O3 |
| Canonical SMILES | CC1=C2C(=CN(C2=NC=N1)C3C(C(C(O3)CO)O)(C)F)C#CC4=CC(=C(C=C4)Br)F |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 706 |
| Exact Mass | 477.04996 |
| In Vitro | ZIKV-IN-1 (compound 38) (0-80 µM) shows anti-ZIKV activity in a dose-dependent manner in A549 cells. ZIKV-IN-1 (5, 10, 25 µM; 48 h) decreases the expression of ZIKV E and cleaved Caspase 3 protein. ZIKV-IN-1 (1.25, 2.5, 5, 10, 20 µM; 0-250 s) shows strong affinity to ZIKV RdRp domain (Kd=1.87 µM) in A549 cells. |
| Target | EC50: 2.8 µM (ZIKV) |
| XLogP3-AA | 3.4 |
